The EndoPredict Score Identifies Late Distant Metastases in ER-Positive, HER2-Negative Breast Cancer


The EndoPredict Score Identifies Late Distant Metastases in ER-Positive, HER2-Negative Breast Cancer
Slides from a presentation at SABCS 2012 and transcribed comments from a recent interview with Lisa A Carey, MD (1/17/13)

Dubsky P et al. The EndoPredict score identifies late distant metastases in ER+/HER2- breast cancer patients. San Antonio Breast Cancer Symposium 2012;Abstract S4-3.

Dr Carey is Richardson and Marilyn Jacobs Preyer Distinguished Professor for Breast Cancer Research, Chief of the Division of Hematology and Oncology, Physician-in-Chief at the North Carolina Cancer Hospital and Associate Director for Clinical Research at the Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina.